Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer

Table 6 Clinical trials of second-generation epidermal growth factor receptor tyrosine kinase inhibitors (afatinib, dacomitinib) against non-small cell lung cancer expressing activated mutant epidermal growth factor receptor

Ref.	Phase	Treatment	Number of patients	Response rate (%)	PFS (mo)	OS (mo)
LUX-Lung 2[46]	II	Afatinib	106a	66	15.0	32
LUX-Lung 3[47]	III	CDDP + PEM	104	NE	6.9	NE
		Afatinib	204	NE	13.6	NE
LUX-Lung 6[48]	III	CDDP+GEM	122	23	5.6	NE
		Afatinib	242	67	11.0	NE
Kris et al[51]	III	dacomitinib	46	74	18.2	NE

^aOf the 129 patients enrolled in the study, 106 patients tested positive for activating epidermal growth factor receptor mutations, including the exon 19 deletion mutation and L858R. PFS: Progression-free survival; OS: Overall survival; CDDP: Cisplatin; PEM: Pemetrexed; GEM: Gemcitabine; NE: Not evaluated.